



Technosphere Inhaled Insulin: Is Faster Better?

Jack L. Leahy

Diabetes Care 2015;38:2282–2284 | DOI: 10.2337/dci15-0002

Pulmonary-delivered insulin is again a reality (1). The failure of the first inhaled insulin in 2007 showed that being radically different from what health care providers are used to, even when injections are avoided, can be problematic. The current product Technosphere inhaled insulin has addressed many of the prior concerns—a more convenient delivery device that is dosed in insulin units. Also, fear of lung toxicity or tumor development has been lessened somewhat by *in vitro* cytotoxic (2) and *in vivo* clearance (3) studies, plus a 2-year clinical trial showed no differences in pulmonary imaging or function in Technosphere-treated and untreated subjects with diabetes (4). In addition, aerosolized medicines that have effective absorption into the bloodstream are well established (5), with numerous agents having been tried including glucagon-like peptide 1 (6).

A highly touted feature of pulmonary-delivered insulin is its *rapid* absorption—peak absorption by 10–15 min and fully cleared by 2–3 h versus a peak of 45–60 min and clearance of 5–6 h for injected analog prandial insulins (1,7) (Fig. 1). The potential importance of an ultrafast “on response” relates to the phasic nature of endogenously secreted insulin. An intravenous glucose infusion in humans without diabetes elicits a distinct first phase of insulin secretion over the first 10 min that is followed by a short

lull and then a sustained second phase for the duration of the hyperglycemia. Actually, the diverse nutrient makeup of meals and their oral delivery initiate a more broad-based insulin response that does not separate into distinct phases. Still, the early insulin that is secreted into the portal vein serves a key role to rapidly turn off hepatic glucose production (8) and likely contributes to the fall in glucagon and controlled rise and fall in circulating free fatty acids that collectively characterize normal prandial metabolism. A defining feature of type 2 diabetes is a near-total absence of the early insulin response, while the later phase is present and often exaggerated because of the hyperglycemia, *i.e.*, mealtime insulin is delayed (9,10). Restoring early insulin with a short-term insulin infusion in type 2 diabetes markedly improved prandial glycemia and lipemia (11). Hence, a reasonable conclusion is the earliest secreted insulin is a necessary element of the normal mealtime insulin response, and consequently optimal exogenous prandial insulin needs a rapid “on response.” And Technosphere insulin is the best we have. However, a question that needs to be answered is whether that difference provides any meaningful clinical advantage over the injected prandial insulins.

Two studies in this issue of *Diabetes Care* provided insight into how this insulin

performs. Bode et al. (12) performed a 24-week noninferiority open-label study of subjects with type 1 diabetes that received injected basal and aspart insulins (basal-bolus) or injected basal and inhaled Technosphere insulin at meals. The main finding was noninferiority with the attained A1C values falling within the agreed-upon study criteria of within 0.4%. The basal-bolus group fell from 7.9% after basal insulin optimization to 7.5% at the end of the study versus 7.9% to 7.7% in the inhaled insulin group. However, the percent of subjects attaining A1C \leq 7% was superior in the injection group (31% vs. 18%), and the 7-point glucose profiles showed better control in the injected insulin group at all times except fasting. Otherwise, there were no major surprises or concerns over the use or safety of inhaled insulin.

Thus, for type 1 diabetes, the fact that inhaled insulin was not more effective than prandial injections and probably less effective (despite meeting the noninferiority criteria) seems predictable as the rapid insulin profile likely runs out too soon on the background of complete insulin deficiency. However, features of inhaled insulin raise novel possibilities that might allow for creative ways to take advantage of its unique action profile. Importantly, Bode et al. found the faster “off time” of inhaled insulin lowered the risk of hypoglycemia 2–5 h

Division of Endocrinology, Diabetes & Metabolism and the Department of Medicine, The University of Vermont, Burlington, VT

Corresponding author: Jack L. Leahy, jleahy@uvm.edu.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

See accompanying articles, pp. 2200, 2204, 2211, 2217, 2226, 2234, 2237, 2241, 2250, 2258, 2266 and 2274.




Figure 1—Pharmacokinetic profiles (mean \pm SE) of inhaled Technosphere insulin and subcutaneously injected rapid-acting insulin analog presented by Cassidy et al. at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, LA, 5–9 June 2009. Reproduced from Boss et al. (7).

after a meal versus the injected prandial insulin. As such, second inhalations 90–120 min after meals, as discussed elsewhere (7), could be a powerful strategy for fine-tuning mealtime insulin coverage while minimizing the risk of hypoglycemia, especially if used with continuous glucose monitoring. A second intriguing possibility is using inhaled insulin together with injected prandial insulin to get an early insulin boost. Technosphere insulin added at the start of a meal with a closed-loop pump system has been shown to result in superior mealtime glycemic control (13,14).

The study by Rosenstock et al. (15) is a 24-week comparison in subjects with type 2 diabetes poorly controlled with oral antidiabetes agents of adding mealtime Technosphere inhaled insulin or a placebo inhalation (the Technosphere matrix fumaryl diketopiperazine) to their usual antidiabetes medications, which were mostly metformin or sulfonylurea and metformin. Thus, a notable aspect of this study is inhaled insulin without basal insulin—a true injection-free program. The main finding was as expected—a statistically superior lowering of A1C with the inhaled insulin from baseline 8.3% to 7.4% versus to 7.8% with the Technosphere placebo. There was also a modest doubling of nonserious hypoglycemia with the inhaled insulin, mostly in sulfonylurea-treated patients. These findings support a smaller, shorter study with a similar protocol (16).

Remembering that the principal prandial insulin secretory defect in type 2 diabetes is a delayed mealtime response (9,10), one might have hoped

for an even lower A1C with the inhaled insulin. Studies with injected prandial insulin alone in type 2 diabetes have shown better A1C values, but with considerably more hypoglycemia (17,18). However, a striking finding in the study by Rosenstock et al. (15) is the 7-point glucose profile: inhaled insulin did a good job at controlling the postmeal values, although a caveat is that the testing was done 90 min after starting the meal, before the insulin effect is over. Failure to see a lower A1C value was shown to be because of no appreciable impact of the inhaled insulin on fasting blood glucose.

Thus, a key question is whether a combination of properly titrated inhaled insulin and injected basal insulin would produce a superior and safer approach than injected basal-bolus insulin in type 2 diabetes. This is reminiscent of how the combination insulin and glucagon-like peptide 1 receptor agonist story evolved—similar overall blood glucose control from different patterns of improvement when twice-daily inhaled exenatide (postprandial) and glargine insulin (fasting and premeal) were used individually (19) but amazing glycemic control when used together (20). So far there is insufficient evidence to know what to expect from the combination of Technosphere insulin and injected basal insulin. A 52-week study of glargine insulin and Technosphere inhaled insulin used together lowered A1C from 8.7% to 8.0% (21). In contrast, A1C values in a study of injected basal-bolus insulin fell from 8.1–8.3% to 6.5–6.7%, but with substantial weight gain and hypoglycemia (22).

In summary, the ultrafast profile of inhaled Technosphere insulin is novel and brings several possibilities. Of particular interest is intensive mealtime insulin coverage with less hypoglycemia through repeat doses or if used with injected prandial insulin. However, these possibilities are more speculative than proven. As such, inhaled insulin is still a convenience product rather than a proven advance in insulin therapy. However, it is at the forefront of several faster insulins that are in development (22,23). And the question remains—is faster better?

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

- Santos Cavaiaola T, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. *Clin Ther* 2014;36:1275–1289
- Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P. Technosphere insulin: defining the role of Technosphere particles at the cellular level. *J Diabetes Sci Technol* 2009;3:545–554
- Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere insulin inhalation powder administration. *Pharm Res* 2011;28:2157–2164
- Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabetes treatment: a randomized trial. *Diabetes Obes Metab* 2012;14:163–173
- Scheuch G, Kohlhaeufel MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. *Adv Drug Deliv Rev* 2006;58:996–1008
- Siekmeier R, Hofmann T, Scheuch G, Pokorski M. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome. *Adv Exp Med Biol* 2015;849:23–38
- Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. *J Diabetes Sci Technol* 2012;6:773–779
- Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. *Am J Physiol* 1989;257:E241–E246
- Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. *J Clin Invest* 1967;46:1954–1962
- Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. *N Engl J Med* 1992;326:22–29
- Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. *Diabetes* 1988;37:736–744
- Bode BW, McGill JB, Lorber DL, Gross JL, Chang P-C, Bregman DB; Affinity 1 Study Group. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. *Diabetes Care* 2015;38:2266–2273
- Lee JJ, Dassau E, Zisser H, Harvey RA, Jovanović L, Doyle FJ 3rd. In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting Technosphere insulin with zone model predictive control. *J Diabetes Sci Technol* 2013;7:215–226
- Zisser H, Dassau E, Lee JJ, Harvey RA, Bevier W, Doyle FJ 3rd. Clinical results of an automated artificial pancreas using Technosphere inhaled insulin to mimic first-phase insulin secretion. *J Diabetes Sci Technol* 2015;9:564–572
- Rosenstock J, Franco D, Korpachev V, et al.; Affinity 2 Study Group. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. *Diabetes Care* 2015;38:2274–2281

16. Rosenstock J, Bergenstal R, Defronzo RA, et al.; 0008 Study Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. *Diabetes Care* 2008;31:2177–2182
17. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *N Engl J Med* 2007;357:1716–1730
18. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *Lancet* 2008;371:1073–1084
19. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2005;143:559–569
20. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med* 2011;154:103–112
21. Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. *Diabetes Care* 2008;31:1305–1310
22. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. *J Diabetes Sci Technol* 2012;6:728–742
23. Cahn A, Miccoli R, Dardano A, Del Prato S. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. *Lancet Diabetes Endocrinol* 2015;3:638–652